HEIDELBERG, Germany, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD) today announced that on November 2, 2016, the Company will release its financial results for the quarter ended September 30, 2016. The Company’s management team will host a conference call to discuss the Company’s financial results and recent corporate developments on Wednesday, November 2, 2016 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 7663835.
|Local - Amsterdam, the Netherlands:||+31 (0) 20 716 8256|
|Local - Copenhagen, Denmark:||+4532 71 16 59|
|Local – Frankfurt, Germany:||+49 (0) 69 2222 10630|
|Local - Geneva, Switzerland:||+41 (0) 22 417 7109|
|Local - London, U.K.:||+44 (0) 20 3140 8286|
|Local - New York City, U.S.A.:||+1 646 254 3362|
|Local - Paris, France:||+33 (0) 1 76 77 22 22|
An audio webcast of the conference call can be accessed in the “Events” section on the “Media” page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed’s website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
Affimed (Nasdaq:AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.GlobeNewswire
Last updated on: 26/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.